Aurinia Pharmaceuticals Inc. (AUPH) concluded trading on 11/17/22 at a closing price of $4.74, with 3.35 million shares of worth about $15.89 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.31% during that period and on Thursday the price saw a loss of about -4.05%. Currently the company’s common shares owned by public are about 141.86M shares, out of which, 132.89M shares are available for trading.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 55 times over the past 12 months. They bought 357,084 shares in 42 of the transactions. In 13 selling transactions, insiders dumped 152,929 shares.
iShares Russell 2000 ETF, Fidelity Advisor Series I -Growth, and iShares Russell 2000 Growth ETF are the top 3 mutual funds which are holding stakes in Aurinia Pharmaceuticals Inc. iShares Russell 2000 ETF is currently holding 2.97 million shares of worth totaling $24.11 million. The company recently came selling 55105.0 shares which brought its stake up to 2.09% of the company’s outstanding shares. iShares Russell 2000 Growth ETF, after buying 1.07 million shares, have now control over 0.76% of the stake in the company. It holds 0.0 shares of worth $8.72 million.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) started trading at $4.80, below -$0.14 from concluding price of the previous day. However, the stock later moved at a day high price of 4.8550, or with a loss of -4.05%. Stock saw a price change of -10.90% in past 5 days and over the past one month there was a price change of -34.17%. Year-to-date (YTD), AUPH shares are showing a performance of -79.27% which decreased to -83.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.82 but also hit the highest price of $30.44 during that period. The average intraday trading volume for Aurinia Pharmaceuticals Inc. shares is 2.49 million. The stock is currently trading -26.19% below its 20-day simple moving average (SMA20), while that difference is down -32.48% for SMA50 and it goes to -53.72% lower than SMA200.
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) currently have 141.86M outstanding shares and institutions hold larger chunk of about 36.10% of that. Holding of mutual funds in the company is about — while other institutional holders and individual stake holders have control over — and — of the stake respectively.
The stock has a current market capitalization of $677.39M and its 3Y-monthly beta is at 0.90. It has posted earnings per share of -$0.83 in the same period. It has Quick Ratio of 10.40 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUPH, volatility over the week remained 5.23% while standing at 8.38% over the month.
Analysts are in expectations that Aurinia Pharmaceuticals Inc. (AUPH) stock would likely to be making an EPS of -$0.17 in the current quarter, while forecast for next quarter EPS is -$0.15 and it is -$0.36 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.25 which is $0 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.39 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -61.40% while it is estimated to decrease by -3.50% in next year.
Analysts at 8 brokerage firms have issued recommendations for the Aurinia Pharmaceuticals Inc. (AUPH)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.10. Out of those 8 Wall Street analysts, 5 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Coverage by Cantor Fitzgerald stated Aurinia Pharmaceuticals Inc. (AUPH) stock as an Overweight in their note to investors on May 05, 2022, suggesting a price target of $25 for the stock. On December 10, 2021, Oppenheimer Upgrade their recommendations, while on October 28, 2021, Oppenheimer Downgrade their ratings for the stock with a price target of $32. Stock get a Buy rating from H.C. Wainwright on January 25, 2021.